Lilly’s STAR Results Show Evista Reduces Breast Cancer Risk; sNDA On Track
This article was originally published in Pharmaceutical Approvals Monthly
Lilly's Evista and AstraZeneca's Nolvadex each reduce the risk of developing invasive breast cancer by roughly 50%, according to initial results from the National Surgical Adjuvant Breast & Bowel Project's Study of Tamoxifen and Raloxifene, released April 17
You may also be interested in...
Lilly will include only one Phase III study in an application for Arxxant use for diabetic retinopathy, the firm said
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011